Satavaptan

Satavaptan is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. It is grouped under the following drug class(es): Diuretics. Its therapeutic use is listed as hyponatremia agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Satavaptan [INN] and Aquilda. Its PubChem CID is 158348.

CAS No 185913-78-4
Molecular Formula C33H45N3O8S
Molecular Weight 643.8 g/mol
Synonyms N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide

Frequently Asked Questions